Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Retained Earnings (2021 - 2025)

Lyra Therapeutics has reported Retained Earnings over the past 5 years, most recently at -$433.7 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$433.7 million for Q4 2025, down 7.14% from a year ago — trailing twelve months through Dec 2025 was -$433.7 million (down 7.14% YoY), and the annual figure for FY2025 was -$433.7 million, down 7.14%.
  • Retained Earnings for Q4 2025 was -$433.7 million at Lyra Therapeutics, down from -$426.8 million in the prior quarter.
  • Over the last five years, Retained Earnings for LYRA hit a ceiling of -$4000.0 in Q2 2024 and a floor of -$433.7 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$264.6 million (2022), compared with a mean of -$266.1 million.
  • Biggest five-year swings in Retained Earnings: soared 100.0% in 2024 and later tumbled 10519250.0% in 2025.
  • Lyra Therapeutics' Retained Earnings stood at -$193.4 million in 2021, then decreased by 28.58% to -$248.7 million in 2022, then dropped by 25.21% to -$311.4 million in 2023, then plummeted by 30.01% to -$404.8 million in 2024, then fell by 7.14% to -$433.7 million in 2025.
  • The last three reported values for Retained Earnings were -$433.7 million (Q4 2025), -$426.8 million (Q3 2025), and -$420.8 million (Q2 2025) per Business Quant data.